|
| 37105206 | Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC). | | 2023 |
| 35871975 | An invisible threat? Aspergillus positive cultures and co-infecting bacteria in airway samples. | Journal of Cystic Fibrosis | 2023 |
| 37624013 | Biologically Relevant Murine Models of Chronic Respiratory Infection. | | 2023 |
| 37286220 | Basic, translational and clinical aspects of bronchiectasis in adults. | | 2023 |
| 36581073 | Omalizumab in Allergic Bronchopulmonary Aspergillosis: A Systematic Review and Meta-Analysis. | | 2023 |
| 37325779 | A systematic review to identify and collate factors influencing patient journeys through clinical trials. | | 2023 |
| 36631132 | Role of inhaled antibiotics in the era of highly effective CFTR modulators. | | 2023 |
| 36548542 | Clinimetric Properties of Outcome Measures in Bronchiectasis. | | 2023 |
| 34998112 | Bronchiectasis and inhaled tobramycin: A literature review. | Respiratory Medicine | 2022 |
| 35451922 | Multiple-Breath Washout Outcome Measures in Adults with Bronchiectasis. | Annals of the American Thoracic Society | 2022 |
| 35764510 | Modulation, microbiota and inflammation in the adult CF gut: A prospective study. | Journal of Cystic Fibrosis | 2022 |
| 36006824 | Whole-genome analysis of strains isolated from persons with cystic fibrosis. | | 2022 |
| 35486871 | Cystic Fibrosis Airway Mucus Hyperconcentration Produces a Vicious Cycle of Mucin, Pathogen, and Inflammatory Interactions that Promotes Disease Persistence. | American Journal of Respiratory Cell and Molecular Biology | 2022 |
| 35549675 | Taxonomic position, antibiotic resistance and virulence factor production by Stenotrophomonas isolates from patients with cystic fibrosis and other chronic respiratory infections. | BMC Microbiology | 2022 |
| 35730434 | Taxonomic position, antibiotic resistance and virulence factors of clinical isolates. | Frontiers in Bioscience - Scholar | 2022 |
| 35408875 | The Effect of CFTR Modulators on Airway Infection in Cystic Fibrosis. | International Journal of Molecular Sciences | 2022 |
| 33958279 | Clinical characteristics of Pseudomonas and Aspergillus co-infected cystic fibrosis patients: A UK registry study. | Journal of Cystic Fibrosis | 2022 |
| 34570994 | Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations. | Lancet Respiratory Medicine,The | 2022 |
| 35265731 | Establishing Antimicrobial Susceptibility Testing Methods and Clinical Breakpoints for Inhaled Antibiotic Therapy. | Open Forum Infectious Diseases | 2022 |
| 34906431 | The journal of cystic fibrosis' 20th anniversary. | Journal of Cystic Fibrosis | 2022 |
| 34538755 | Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis. | Journal of Cystic Fibrosis | 2021 |
| 35368453 | Microbial Community Composition in Explanted Cystic Fibrosis and Control Donor Lungs. | Frontiers in Cellular and Infection Microbiology | 2021 |
| 33898620 | BronchUK: protocol for an observational cohort study and biobank in bronchiectasis. | ERJ Open Res | 2021 |
| 34112603 | Microbial interaction: Prevotella spp. reduce P. aeruginosa induced inflammation in cystic fibrosis bronchial epithelial cells. | Journal of Cystic Fibrosis | 2021 |
| 33895096 | Guiding the rational design of patient-centred drug trials in Cystic Fibrosis: A Delphi study. | Journal of Cystic Fibrosis | 2021 |
| 33888572 | Transepithelial nasal potential difference in patients with, and at risk of acute respiratory distress syndrome. | Thorax | 2021 |
| 33888521 | Psychometrics of health-related quality of life questionnaires in bronchiectasis: a systematic review and meta-analysis. | European Respiratory Journal | 2021 |
| 33828414 | Therapeutic Inhibition of Cathepsin S Reduces Inflammation and Mucus Plugging in Adult ENaC-Tg Mice. | Mediators of Inflammation | 2021 |
| 33609487 | Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study. | Lancet Respiratory Medicine,The | 2021 |
| 33927017 | Time to get serious about the detection and monitoring of early lung disease in cystic fibrosis. | Thorax | 2021 |
| 33653764 | Discrete choice experiment (DCE) to quantify the influence of trial features on the decision to participate in cystic fibrosis (CF) clinical trials. | BMJ Open | 2021 |
| 33549519 | Extended-culture and culture-independent molecular analysis of the airway microbiota in cystic fibrosis following CFTR modulation with ivacaftor. | Journal of Cystic Fibrosis | 2021 |
| 32855225 | Efficacy and safety of TOBI Podhaler in infected bronchiectasis patients: iBEST study. | European Respiratory Journal | 2021 |
| 33011099 | Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosis. | J Cyst Fibros | 2021 |
| 32563724 | Antimicrobial resistance: Concerns of healthcare providers and people with CF. | Journal of Cystic Fibrosis | 2021 |
| 34463860 | Characterization of clinical Ralstonia strains and their taxonomic position. | Antonie van Leeuwenhoek | 2021 |
| 34565704 | Digital healthcare in cystic fibrosis. Learning from the pandemic to innovate future care (Commentary). | Journal of Cystic Fibrosis | 2021 |
| 34384254 | Management of chronic infection with inhaled levofloxacin in people with cystic fibrosis. | Future Microbiology | 2021 |
| 31364220 | Composition of airway bacterial community correlates with chest HRCT in adults with bronchiectasis. | Respirology | 2020 |
| 32198220 | Modulator treatment for people with cystic fibrosis: moving in the right direction. | European Respiratory Review | 2020 |
| 32122785 | Finding the relevance of antimicrobial stewardship for cystic fibrosis. | Journal of Cystic Fibrosis | 2020 |
| 31680041 | Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices. | Journal of Cystic Fibrosis | 2020 |
| 32238195 | Lung function and microbiota diversity in cystic fibrosis. | Microbiome | 2020 |
| 31767727 | Susceptibility of Pseudomonas aeruginosa Recovered from Cystic Fibrosis Patients to Murepavadin and 13 Comparator Antibiotics. | Antimicrobial Agents and Chemotherapy | 2020 |
| 32218627 | STAPHYLOCOCCUS AUREUS ENTEROTOXINS IN PEOPLE WITH CYSTIC FIBROSIS (CF). | | 2020 |
| 32217675 | Draft Genome Sequence of a Haemophilus parainfluenzae Strain Isolated from a Patient with Chronic Obstructive Pulmonary Disease. | Microbiology Resource Announcements | 2020 |
| 31812487 | Influence of azithromycin and allograft rejection on the post-lung transplant microbiota. | Journal of Heart and Lung Transplantation | 2020 |
| 31607634 | Infection with Prevotella nigrescens induces TLR2 signalling and low levels of p65 mediated inflammation in Cystic Fibrosis bronchial epithelial cells. | Journal of Cystic Fibrosis | 2020 |
| 33093704 | TACKLING ANTIMICROBIAL RESISTANCE (AMR) - IN VITRO EFFECT OF SODIUM CHLORIDE ON ANTIBIOTIC SUSCEPTIBILITY IN CLINICAL PSEUDOMONAS AERUGINOSA ISOLATED FROM PATIENTS WITH CYSTIC FIBROSIS (CF). | | 2020 |
| 33141825 | Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: Lessons learned from the first ataluren phase 3 study. | PLoS One | 2020 |